- Open Access
PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway
Journal of Experimental & Clinical Cancer Research volume 36, Article number: 85 (2017)
PHF21B is newly identified to be involved in the tumor progression; however, its biological role and molecular mechanism in prostate cancer have not been defined. This study is aimed to study the role of PHF21B in the progression of prostate cancer.
Real-time PCR, immunohistochemistry and western blotting analysis were used to determine PHF21B expression in prostate cancer cell lines and clinical specimens. The role of PHF21B in maintaining prostate cancer stem cell-like phenotype was examined by tumor-sphere formation assay and expression levels of stem cell markers. Luciferase reporter assay, western blot analysis, enzyme-linked immunosorbent assay and ChIP assay were used to determine whether PHF21B activates the Wnt/β-catenin signaling by transcriptionally downregulating SFRP1 and SFRP2.
Our results revealed that PHF21B was markedly upregulated in prostate cancer cell lines and tissues. High PHF21B levels predicted poorer recurrence-free survival in prostate cancer patients. Gain-of-function and loss-of-function studies showed that overexpression of PHF21B enhanced, while downregulation suppressed, the cancer stem cell-like phenotype in prostate cancer cells. Xenograft tumor model showed that silencing PHF21B decreased the ability of tumorigenicity in vivo. Notably, Wnt/β-catenin signaling was hyperactivated in prostate cancer cells overexpressing PHF21B, and mediated PHF21B-induced cancer stem cell-like phenotype. Furthermore, PHF21B suppressed repressors of the Wnt/β-catenin signaling cascade, including SFRP1 and SFRP2. These results demonstrated that PHF21B constitutively activated wnt/β-catenin signaling by transcriptionally downregulating SFRP1 and SFRP2, which promotes prostate cancer stem cell-like phenotype.
Our results revealed that PHF21B functions as an oncogene in prostate cancer, and may represent a promising prognostic biomarker and an attractive candidate for target therapy of prostate cancer.
Prostate cancer (PCa), one of the most lethal malignancies, constitutes 19% of all cancers diagnosed in men, with an estimated 161,360 new cases in the United States in 2017 . While clinically localized PCa can be well controlled through radical prostatectomy, the 10-year recurrence rate in the intermediate and high risk localized PCa cases was 54% and 71%, respectively , leading to insurmountable obstacles for improving the survival rate [3, 4]. For patients with advanced prostate cancer, androgen deprivation therapy (ADT) has been the standard therapy. However, most patients relapse and develop castration-resistant prostate cancer within 18–24 months following ADT . Cancer stem cells (CSCs), a small subpopulation of cancer cells, which possess self-renewal and multilineage differentiation potential, have been reported to play a critical role for PCa [6, 7]. CSCs are responsible for tumor initiation, chemotherapy resistance and become enriched after ADT treatment, which leads to poor outcomes and recurrence in PCa patients [8,9,10,11,12,13]. Therefore, unveiling the underlying molecular mechanism of prostate CSCs turns out to be the essential and profound topic for PCa treatment.
The Wnt/β-catenin signaling pathway, which is one of the most relevant pathways involved in CSCs, has been reported to be aberrantly activated in various types of cancers, including PCa [14,15,16]. Previous studies have shown that canonical Wnt signaling passway is associated with chemoresistance and recurrence of PCa [17,18,19,20]. Yun et al. reported that DAB2IP knockdown promotes PCa stem cell phenotypes through activation of Wnt/β-catenin signaling, and increases PCa cells chemoresistance . Moreover, Huang et al. revealed that genetic variations of adenomatous polyposis coli (APC), tumor suppressor involved in the Wnt signaling pathway by regulating β-catenin degradation and nuclear export, are associated with recurrence of PCa following radical prostatectomy . However, the underlying mechanism of how Wnt/β-catenin signaling regulates prostate CSCs remains to be elucidated.
Wnt/β-catenin signaling is initiated by the binding of Wnt to Frizzled (FZD) receptor and LRP-5/6, leading to the stabilization of cytosolic β-catenin [21, 22]. β-catenin then translocates to the nucleus and regulates the expression of a number of genes implicated in prostate CSCs regulation [13, 23]. On the other hand, there are several negative modulators involved in the Wnt/β-catenin signaling pathway for fine tuning the signaling. For instance, secreted Frizzled-related proteins (SFRPs), extracellular secreted Wnt inhibitors, can suppress Wnt ligands binding to frizzled receptor and block signal transduction . Axin, GSK-3β and APC cause a robust suppression in the activity of Wnt/β-catenin signaling by forming a destruction complex and inducing β-catenin degradation . Thus, understanding how these negative regulatory effects on the Wnt/β-catenin signaling pathway is clinically important for future development of PCa treatment.
Previous study has shown that proteins of the PHD zinc finger superfamily are capable of translocating to the nucleus and regulating transcription of genes, and involve in tumor progression in various types of cancers, including PCa [26,27,28,29]. High levels of PHF8 were associated with high Gleason grade and poor prognosis in PCa, and strengthened PCa cell migration and invasion in vitro . Moreover, recently, Lapuk et al. found that PHF21A is differentially spliced in highly proliferative and aggressive neuroendocrine prostate cancer (NEPCa) versus PCa , in which these alternatively spliced genes were involved in EMT and important for cell shape and invasion. PHF21B, encoding the PHD finger protein 21B, is homologous to PHF21A and acts as a transcriptional repressor like PHF21A . Previous study has reported that PHF21B was downregulated in head and neck squamous cell carcinomas (HNSCC), and reduced MDA-MB231 cells migration and colony formation in vitro . However, the clinical implications and function of PHF21B in PCa have not been defined. In the present study, we found that PHF21B was significantly overexpressed in PCa and enhanced the stem cell-like traits of PCa cells by downregulating of negative modulators of the Wnt/β-catenin pathway, including SFRP1 and SFRP2. Therefore, our results suggest that PHF21B might serve as a novel therapeutic target in PCa.
Cell lines and cell culture
RWPE-1, PC-3, DU145, C4-2B, VCaP and LNCaP cells were obtained from the ATCC (Manassas, VA, USA). RWPE-1 cells were cultured in defined keratinocyte-SFM (1×) (Invitrogen, Carlsbad, CA, USA). PC-3, C4-2B and LNCaP cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with10% FBS (Invitrogen), while DU145 and VCaP cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with10% FBS.
Patient information and tissue specimens
A total of 116 paraffin-embedded and archived PCa samples were collected for this study, which had been diagnosed histopathologically. Clinical information on the samples is summarized in detail in Additional file 1: Table S1. The fresh tissues including eight paired PCa tissues and adjacent non-tumor tissues were obtained from individuals who were diagnosed with PCa. All samples were collected from the First Affiliated Hospital of Sun Yat-sen University. Prior patient's consents were obtained to use these clinical specimens for research purposes. Our study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University according to the 1975 Declaration of Helsinki.
Plasmids, virus constructs and retroviral infection of target cells
A human PHF21B cDNA clone (EX-T2701-Lv105), as well as short hairpin RNA (shRNA) expression clone (HSH001525-CU6), was purchased from GeneCopoeia (Guangzhou, China). SMARTpool siRNA against human SFRP1, SFRP2, and β-catenin was purchased from RiboBio (Guangzhou, China). The reporter plasmids containing wild-type (CCTTTGATC; TOP flash) or mutated (CCTTTGGCC; FOP flash) TCF/LEF DNA binding sites were purchased from Upstate Biotechnology (New York, USA). Transfection of plasmids or siRNA was performed using the Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instruction. Stable cell lines expressing PHF21B and PHF21B-shRNA were generated by retroviral infection and selected with 0.5 μg/ml puromycin for 10 days.
RNA extraction, reverse transcription (RT) and real-time PCR
Total RNA was extracted from cultured cells and PCa tissues using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. A total of 2 μg of RNA was reverse transcribed to cDNA with M-MLV Reverse Transcriptase (Promega, Madison, US). qRT-PCR analysis was performed on an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Texas, US). Expression data were normalized to the housekeeping gene GAPDH. Relative expression levels were calculated as 2-[(Ct of gene) - (Ct of GAPDH)], in which Ct represents the threshold cycle for each transcript. The PCR primer sequences are listed in Additional file 2: Table S2.
Western blotting was performed as described previously , using anti-PHF21B (ab70435, 1:1000; Abcam, Cambridge, UK), anti-β-catenin (#9562, 1:1000; Cell Signaling, Danvers, MA, USA), anti-phospho-β-Catenin (Ser33/37/Thr41) (#9561, 1:1000; Cell Signaling), and anti-p84 (ab102684, 1:500; Abcam) antibodies. Blotting membranes were stripped and re-probed with anti-α-tubulin antibody (T6199, 1:2000; Sigma-Aldrich, St. Louis, MO, USA) as a loading control. Nuclear extracts were prepared using the Nuclear Extraction kit (Active Motif), according to the manufacturer's instructions.
Immunohistochemical (IHC) analysis was conducted to study protein expression in clinical specimens. The procedure was carried out similarly to previously described methods . After deparaffinization, the sections were immunohistochemically stained using anti-PHF21B (HPA053834, 1:2500; Sigma-Aldrich), and anti-β-catenin antibody (#9562, 1:200; Cell Signaling). The degree of immunostaining offormalin-fixed, paraffin-embedded sections was examined and scored independently by two pathologists. The scores were determined by combining the proportion of positively stained tumor cells and the intensity of the IHC signals. Tumor cell proportions were scored as follows: 0, no positive tumor cells; 1, 1%-25% positive tumor cells; 2, 25%-50% positive cells; 3, 50%-75% positive tumor cells; and 4, >75% positive tumor cells. Staining intensity was graded according to the following criteria: 0, no staining; 1, weak staining (light yellow); 2, moderate staining (yellow brown); and 3, strong staining (brown). The staining index (SI) was calculated as the staining intensity score × the proportion of positive tumor cells (ranging from 0 to 12). We evaluated protein expression by determining the SI. Samples with an SI ≥ 6 were classified as showing high expression, while samples with an SI < 6 were classified as showing low expression.
Enzyme-linked immunosorbent assay (ELISA)
Using a commercially available SFRP1 (E95880Hu) and SFRP2 (E95879Hu) ELISA Kit (USCN, Wuhan, China), the concentration of SFRP1 and SFRP2 in the conditioned media (CM) derived from the cells was determined. ELISA was performed according to the directions of the manufacturer.
Sphere formation assay
Cells (500/well) were seeded into 6-well ultra-low cluster plates (Corning, NY) and cultured in DMEM/F12 serum-free medium (Invitrogen) supplemented with 2% B27 (Invitrogen), 20 ng/ml EGF (PeproTech, Rocky Hill, NJ, USA), 20 ng/ml bFGF (PeproTech), 0.4% BSA (Sigma-Aldrich), and 5 μg/ml insulin (Sigma-Aldrich). After 10 days, the number of spheres was counted, and images of the spheres were photographed.
Luciferase activity assay
Thirty thousand cells were cultured in triplicate in 48-well plates for 24 h. Then, 100 ng of luciferase reporter plasmids containing the SFRP1 and SFRP2 promoter, TOP-Flash or FOP-Flash luciferase reporter, plus 3 ng of pRL-TK Renilla plasmid (Promega), were transfected into cells using the Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s recommendations. Luciferase and Renilla signals were measured 36 h after transfection using the Dual Luciferase Reporter Assay Kit (Promega) according to the manufacturer’s protocol.
Specific primers used for promoter luciferase reporter were presented in Additional file 3: Table S3.
The promoter sequences of SFRP1/2 were obtained from the UCSC Genome Browser (http://genome.ucsc.edu) referring the enrichment of H3K27Ac mark (often found near active regulatory elements) on seven cell lines as determined by ChIP-seq assays provided by the website. Each of the cell lines including GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, NHLF in this track is consistent across the ENCODE (Encyclopedia of DNA Elements) Regulation super-track.
Chromatin immunoprecipitation (ChIP)
The SimpleChIP Enzymatic Chromatin IP Kit with magnetic beads (#9003, Cell Signaling, Danvers, MA, USA) was used according to the manufacturer's protocol. Cells (4 × 106) transfected with Flag-tagged PHF21B (EX-T2701-Lv102; GeneCopoeia, Guangzhou, China) in a 100 mm culture dish were treated with formaldehyde to cross-link proteins to DNA. 1× Glycine was added to terminate cross-linking. A total of 5 μg of anti-FLAG antibody (SAB4200071; Sigma, St Louis, MO, USA),) or anti-IgG antibody was incubated with 10 μg of sheared chromatin overnight at 4 °C. ChIP-grade protein G magnetic beads were added and incubated for 2 h at 4 °C with rotation. Immunoprecipitated chromatin was then washed with low- and high-salt ChIP buffer. After reverse cross-linking of protein/DNA complexes to free DNA, PCR was performed. Primers used for ChIP are presented in Additional file 4: Table S4–S5.
Xenograft tumor model
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University. Male BALB/c-nude mice (4–6 weeks old, 18–20 g) were purchased from the Slac-Jingda Animal Laboratory (Hunan, China) and housed in barrier facilities on a 12-h light/dark cycle. Mice were randomly allocated into groups (n = 6 per group). The indicated cells at three doses (1 × 106, 1 × 105, and 1 × 104) were inoculated subcutaneously with Matrigel (final concentration of 25%) into the inguinal folds of the mice. Tumor volume was determined using an external caliper and calculated using the equation (L × W2)/2. After mice were sacrificed, the tumors were excised, weighed and subjected to pathologic examination. The frequency of tumor-initiating cells (TICs) was calculated using the Extreme Limiting Dilution Analysis (ELDA) program (http://bioinf.wehi.edu.au/software/elda/) .
All statistical analyses were carried out using the SPSS 17.0 statistical software package (SPSS Inc, Chicago, IL, USA). The relationship between PHF21B expression and the clinicopathological characteristics was tested by the χ 2 test. Bivariate correlations between study variables were calculated using Spearman's rank correlation coefficients. Survival curves were plotted with the Kaplan-Meier method and compared by the log-rank test. Other comparisons were analyzed by unpaired two-sided independent Student’s t-test without equal variance assumption. P < 0.05 was considered statistically significant.
Expression of PHF21B is upregulated in PCa cell lines and tissues
By analysis of the RNA expression data from The Cancer Genome Atlas (TCGA), we found that PHF21B levels were significantly upregulated in human PCa tissues (n = 497) compared with that in normal prostate tissues (n = 52) (P < 0.001) (Fig. 1a). Overexpression of PHF21B in PCa was confirmed by analyzed prostate cancer GEO dataset GSE21032 (Fig. 1b). We further verified this result in PCa cell lines and paired tissues using realtime PCR and western blotting analysis. As shown in Fig. 1c-f, PHF21B expression levels were differentially increased in five PCa cell lines than that in normal prostate epithelial cell (RWPE-1), and in 8 PCa tissues (T) compared to that in the paired adjacent normal tissues (ANT). Collectively, these results suggested that PHF21B was upregulated and might be involved in human PCa progression.
Upregulation of PHF21B correlates with progression and poor prognosis in PCa
To investigate the clinical significance of upregulation of PHF21B in PCa, PHF21B protein expression was examined in 116 paraffin-embedded, archived PCa tissues using IHC. As shown in Fig. 2a-b and Additional file 1: Table S1, expression of PHF21B correlated significantly with tumor stage (P = 0.011), total PSA level (P = 0.005) and Gleason score (P = 0.001) in PCa. We further assessed the correlation between PHF21B expression and the prognosis of the patient by analyzing the TCGA prostate adenocarcinoma (PRAD) dataset. Notably, Kaplan-Meier survival analysis revealed that patients with high PHF21B expression had poorer recurrence-free survival (RFS) than patients with low PHF21B expression in TCGA (Fig. 2d, P = 0.022), indicating that PHF21B may have potential as an independent prognostic marker in PCa.
PHF21B regulates the stem cell-like phenotype in PCa cells
It has been noted that obtaining a stem-like phenotype of PCa cells is critical for malignant tumor and high frequency of recurrence [8, 9]. We then investigated the role of PHF21B upregulation in the self-renewal ability of PCa cells. PCa cell lines C4-2B and PC-3 were engineered to overexpress or silence PHF21B via lentivirus infection (Fig. 3a-b). Sphere-formation assays showed that upregulating PHF21B increased, while downregulating PHF21B decreased, the number and size of tumor spheroids in C4-2B and PC-3 cells (Fig. 3c). In addition, pluripotency-associated markers, including NANOG, OCT4, SOX2, Bmi1 and c-Myc, showed significantly higher mRNA expression in PHF21B-transduced cells but much lower in PHF21B-silenced cells than in the control group (Fig. 3d-e). Thus, our results indicated that PHF21B promoted the stem cell-like phenotype in PCa.
PHF21B promotes PCa cells tumorigenicity in vivo
To further confirm the effect of PHF21B on PCa cell stemness, we subcutaneously inoculated different numbers of cells mixed with matrigel into the inguinal folds of BALB/c-nude mice. As shown in Fig. 4a-d, the tumors formed by PHF21B-transduced PCa cells, at both amount of 1 × 106, 1 × 105 or 1 × 104 cells, were dramatically larger than the vector control tumors. Conversely, PHF21B-silenced cells formed much smaller tumors and presented lower rates of tumorigenicity (Fig. 4a-d). Importantly, only PHF21B-transduced cells could form tumors when 1 × 104 cells were implanted (Fig. 4d). These results indicated that PHF21B strongly promoted PCa tumorigenicity in vivo.
PHF21B activates Wnt/β-catenin signaling pathway
Since Wnt/β-catenin signaling is one of the most important pathways in maintaining stem cell phenotype and frequently activates in PCa [16, 23], we then examined the role of PHF21B in Wnt/β-catenin signaling pathway. As shown in Fig. 5a, cellular fractionation and western blot analysis revealed that overexpression of PHF21B increased, while silencing of PHF21B reduced nuclear β-catenin expression. In addition, we found that PHF21B overexpression significantly increased, but silencing PHF21B reduced the TCF/LEF activities in PCa cell lines (Fig. 5b). Consistently, the expression of MYC, CD44, SOX9, MMP7, CCND1, LEF1, and NRCAM, which are well-characterized downstream targets of Wnt/β-catenin, were significantly increased in PHF21B-transduced cells but reduced in PHF21B-silenced cells (Fig. 5c). Collectively, our results suggested that PHF21B activated Wnt/β-catenin signaling pathway in PCa.
We further investigated the functional significance of Wnt/β-catenin signaling activation in PHF21B-mediated self-renewal of PCa cells by silencing β-catenin in PHF21B-overexpressing PCa cell lines (Fig. 5d). As expected, the stimulatory effect of PHF21B on TOP/FOP luciferase reporter activity was impaired by silencing β- catenin (Fig. 5e). Moreover, sphere formation assays indicated that silencing β- catenin abrogated the promotive effects of PHF21B on self-renewal of PCa cells (Fig. 5f). Thus, these results reveal that activation of Wnt/β-catenin signaling was essential for PHF21B-promoted stem cell-like phenotype in PCa.
PHF21B suppresses the repressors of Wnt/β-catenin signaling pathway
PHF21B, with a PHD zinc finger domain, localizes to the nucleus and acts as a transcriptional repressor like PHF21A . To investigate the mechanism by which PHF21B activates Wnt/β-catenin signaling passway, we examined whether PHF21B regulates the transcription of negative modulators in Wnt/β-catenin signaling. Indeed, SFRP1 and SFRP2 mRNA and protein expression were both downregulated in PHF21B-transduced PCa cells but upregulated in PHF21B-silenced PCa cells compared with control cells, revealing that SFRP1 and SFRP2 might be transcriptionally downregulated by PHF21B in PCa cells (Fig. 6a-d). As expected, luciferase reporter assays revealed that overexpression of PHF21B attenuated, whereas downregulation of PHF21B activated, the luciferase activity of SFRP1 and SFRP2 promoters in PCa cells in a dose-dependent manner (Fig. 6e-f). Furthermore, ChIP assays revealed that PHF21B was capable of binding to different fragment regions within the SFRP1 and SFRP2 promoters (Fig. 6e-f), suggesting that PHF21B transcriptionally downregulated SFRP1 and SFRP2 expression by directly targeting the SFRP1 and SFRP2 promoters.
In addition, individual silencing of SFRP1 or SFRP2 potently rescued the TOP/FOP luciferase reporter activity and self-renewal ability in PHF21B-silenced cells (Fig. 6g-h and Additional file 5: Figure S1a-b), revealing that SFRP1 and SFRP2 were functional effectors of PHF21B on regulating Wnt/β-catenin signaling and stem cell-like phenotype in PCa. Moreover, as shown in the Figure S1a-b, SFRP1 was not significantly affected by SFRP2 siRNA, and SFRP1 siRNA had no effect on the SFRP2 levels, in PHF21B-RNAi#1 PCa cells, suggesting that either SFRP1 or SFRP2 siRNA rescued TOPflash activity and self-renewal ability in PHF21B-silenced cells was not attributed to the siRNA cross-reaction. Collectively, our results suggested that PHF21B activated Wnt/β-catenin signaling to enhance stem cell-like phenotype in PCa by transcriptionally downregulated SFRP1 and SFRP2.
Clinical relevance of PHF21B and β-catenin in human PCa
IHC analysis of PCa tissue specimens showed that PHF21B was positively correlated with β-catenin expression levels (P < 0.001, Fig. 7a). Collectively, these data further support the notion that PHF21B upregulation in PCa activates canonical Wnt/β-catenin signaling, ultimately leading to PCa progression.
Despite many recent advances, PCa continues to be the leading cause of male cancer-related mortality and morbidity. Most of PCa patients diagnosed with clinically localized disease can be successfully controlled by definitive treatments-radical prostatectomy or radiotherapy alone or in combination with androgen ablation. However, the 10-year recurrence rate is very high [2, 34]. In addition, almost all advanced PCa patients relapse and progress to lethal castration-resistant disease after initial response to androgen ablation . The CSC has been proposed to be responsible for the high rate of relapse and subsequent resistance of advanced PCa to ADT. CSCs have been identified in many solid malignancies, including PCa , and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and progression of castration-resistant PCa [13, 17, 35].
Herein, we found that PHF21B acted as a potent CSC-promoting factor in PCa. Overexpression of PHF21B promoted, while downregulation reduced, the self-renewal of PCa cells and the expression of pluripotency-associated markers, including NANOG, OCT4, SOX2, Bmi1 and c-Myc. In addition, inhibition of PHF21B potentially reduced PCa cells tumorigenicity in vivo. Thus, our results suggested that upregulation of PHF21B is involved in the malignant progression of PCa, and proposed that PHF21B might be a potential therapeutic target for human PCa.
Wnt/β-catenin signaling pathway plays a key role in the regulation of CSC self-renewal and is aberrantly activated in PCa [14, 23]. In addition, the functions of Wnt/β-catenin signaling in PCa development and progression have been well documented. Mesd, a general Wnt inhibitor, suppressed Wnt/β-catenin signaling induced by Wnt1 in PC-3 cells, and inhibited PC-3 cells tumorigenicity in vivo . Unlike in colon cancer, the mutations in β-catenin are rare, but the expression and/or nuclear localization of β-catenin are often abnormal in PCa, suggesting a constitutive activation of Wnt/β-catenin signaling [20, 37, 38]. However, how cancer cells escape the negative regulation by Wnt/β-catenin signaling cascade, leading to constitutively activated β-catenin/TCF remains unclear. Herein, we found that PHF21B was upregulated in PCa and induced activation of Wnt/β-catenin signaling via directly transcriptionally downregulating SFRP1 and SFRP2. Therefore, our findings not only confirmed activation of Wnt/β-catenin pathway contributes to the malignant behavior of PCa, but also revealed a novel mechanism for activation of Wnt/β-catenin pathway involving PHF21B in PCa.
In our result, we found that PHF21B was positively correlated with β-catenin expression levels in PCa tissue specimens (P < 0.001) (Fig. 7a). However, we also observed that 12 of 49 cases (~24%) of PCa with high PHF21B exhibited low protein level of β-catenin. Previous studies have found that human cancers exhibit substantial intra-tumor heterogeneity in transcriptional identities and gene expression . Therefore, the mechanisms by which β-catenin protein is reduced in PCa tissues with high PHF21B might be attributed to tumor heterogeneity. Moreover, there might be some transcriptional cofactors  that bind PHF21B or block associations between PHF21B and the SFRP1 and SFRP2 promoters, under certain circumstances, thus inhibit trans-inactivation of SFRP1 and SFRP2. In addition, recruitment of chromatin-modifying factors might be another reason . In this respect, further investigation of the mechanisms by which β-catenin protein is reduced in PCa with high PHF21B will eventually lead to the development of a new therapeutic strategy for the treatment of PCa.
PHF21B has been reported to be downregulated in HNSCC, and overexpression of PHF21B reduced MDA-MB231 cells migration and colony formation in vitro, suggesting it might act as a tumor suppressor in HNSCC and breast cancer . However, in the current study, PHF21B was significantly upregulated in PCa, and enhanced the stem cell-like traits of PCa cells by activating the Wnt/β-catenin pathway. Therefore, the PHF21B may display both tumor suppressive and oncogenic properties depending on the tissue types and cellular conditions.
In summary, this study provided the first report of the expression of PHF21B in PCa cell lines and tissues, and demonstrated that upregulation of PHF21B may contribute to the progression and poor prognosis of human PCa. Moreover, these data suggests that PHF21B functioned as an oncogene in PCa and may represent a promising prognostic biomarker for PCa. Therefore, this study elucidated the precise role of PHF21B in PCa, and may help to identify more effective therapeutic strategies for PCa.
Androgen deprivation therapy
Adenomatous polyposis coli
Cancer stem cell
Extreme Limiting Dilution Analysis
Enzyme-linked immunosorbent assay
Short hairpin RNA
The Cancer Genome Atlas.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Richie JP, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001;166:2185–8.
D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–83.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.
Wong YN, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol. 2014;11:365–76.
Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Rhim JS, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 2007;67:3153–61.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.
Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8:545–54.
Mimeault M, Mehta PP, Hauke R, Batra SK. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev. 2008;29:234–52.
Li C, Liu S, Yan R, Han N, Wong KK, Li L. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. Theranostics. 2017;7:67–80.
Li P, Yang R, Gao WQ. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer. 2014;13:55.
Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Chang C, et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol. 2013;5:14–26.
Yun EJ, Zhou J, Lin CJ, Hernandez E, Fazli L, Gleave M, Hsieh JT. Targeting cancer stem cells in castration-resistant prostate cancer. Clin Cancer Res. 2016;22:670–9.
Kypta RM, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9:418–28.
Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653;2003:1–24.
Zhu HN, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Kypta RM, et al. Analysis of Wnt gene expression in prostate cancer: Mutual enhibition by WNT11 and the androgen receptor. Cancer Res. 2004;64:7918–26.
Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J, Gao X, et al. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. Int J Oncol. 2016;49:1679–85.
Huang SP, Ting WC, Chen LM, Huang LC, Liu CC, Chen CW, Bao BY, et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol. 2010;17:312–22.
Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, Leung HY, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 2014;66:32–9.
de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Chopin D, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 2003;9:1801–7.
Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 2005;65:9762–70.
Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y. Silibinin inhibits Wnt/beta-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal. 2012;24:2291–6.
Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009;19:683–97.
Malinauskas T, Jones EY. Extracellular modulators of Wnt signalling. Curr Opin Struct Biol. 2014;29:77–84.
Kimelman D, Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006;25:7482–91.
Wei M, Liu B, Su L, Li J, Zhang J, Yu Y, Gu Q, et al. A novel plant homeodomain finger 10-mediated antiapoptotic mechanism involving repression of caspase-3 in gastric cancer cells. Mol Cancer Ther. 2010;9:1764–74.
Kechavarzi B, Janga SC. Dissecting the expression landscape of RNA-binding proteins in human cancers. Genome Biol. 2014;15:R14.
Bjorkman M, Ostling P, Harma V, Virtanen J, Mpindi JP, Rantala J, Nees M, et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene. 2012;31:3444–56.
Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Collins CC, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012;227:286–97.
Bertonha FB, Barros Filho Mde C, Kuasne H, Dos Reis PP, da Costa Prando E, Munoz JJ, et al. Rogatto SR. PHF21B as a candidate tumor suppressor gene in head and neck squamous cell carcinomas. Mol Oncol. 2015;9:450–62.
Wang HQ, Xu ML, Ma J, Zhang Y, Xie CH. Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem Biophys Res Commun. 2012;417:62–6.
Li X, Liang W, Liu J, Lin C, Wu S, Song L, Yuan Z. Transducin (beta)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling. Breast Cancer Res. 2014;16:465.
Hu Y, Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70–8.
Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, D'Este C, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12:451–9.
Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006;5:1886–901.
Lin C, Lu W, Zhai L, Bethea T, Berry K, Qu Z, Li Y, et al. Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo. FEBS Lett. 2011;585:3120–5.
Morin PJ. Activation of beta -Catenin-Tcf Signaling in Colon Cancer by Mutations in beta -Catenin or APC. Science. 1997;275:1787–90.
Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res. 1998;58:2520–3.
Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, Quake SR, et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol. 2011;29:1120–7.
Latchman DS. Transcription factors: bound to activate or repress. Trends Biochem Sci. 2001;26:211–3.
Dilworth FJ, Fromental-Ramain C, Yamamoto K, Chambon P. ATP-driven chromatin remodeling activity and histone acetyltransferases act sequentially during transactivation by RAR/RXR In vitro. Mol Cell. 2000;6:1049–58.
This work was supported by grants from the National Natural Science Foundation of China (No. 81472505) and Science and Technology Planning Project of Guangzhou, China (No.201607010213).
Availability of data and materials
All data are fully available without restriction.
All samples and clinical data were collected from the First Affiliated Hospital of Sun Yat-sen University. Prior patient's consents were obtained to use these clinical specimens for research purposes. Our study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University according to the 1975 Declaration of Helsinki. All animal experiments were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University.
Consent for publication
All contributing authors agree to the publication of this article.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Correlation between PHF21B expression and clinicopathological characteristics of prostate cancer patients. (DOC 38 kb)
Real-time PCR primers. (DOC 37 kb)
The primers used for promoter luciferase reporter. (DOC 29 kb)
The primers used for ChIP assay. (DOC 50 kb)
SFRP1 and SFRP2 protein expression in the indicated cells. (A-B) Enzyme-linked immunosorbent assay (ELISA) analysis of protein levels of SFRP1 (A) and SFRP2 (B) in the supernatants of PHF21B-RNAi#1-C4-2B and -PC-3 cells treated with SFRP1 or SFRP2 siRNA. Error bars represent the means ± SD of 3 independent experiments. *P < 0.05. Not significant, n.s.. (TIF 103 kb)
About this article
Cite this article
Li, Q., Ye, L., Guo, W. et al. PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 36, 85 (2017). https://doi.org/10.1186/s13046-017-0560-y
- Prostate cancer
- Cancer stem cell
- Wnt/β-catenin signaling